Drug Profile
Research programme: oncolytic viral immunotherapies - Turnstone Biologics
Alternative Names: Ad/MG1-hDCT; MG1 Maraba; MG1-Maraba virotherapyLatest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Turnstone Biologics
- Class Cancer vaccines; Oncolytic viruses
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for preclinical development in Prostate-cancer in Canada (Parenteral)
- 29 Mar 2019 Pharmacodynamics data from a preclinical trial in Cancer presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)
- 10 Oct 2017 AbbVie enters into an option license agreement with Turnstone Biologics for its oncolytic viral immunotherapies